Thus, both miR-23b-3p and miR-199a-3p, which correlated to urinary symptoms, have been reported as downregulated in MS inflammatory lesions, which was compatible to our findings in the pre-CLA profiling, and were then reverted by the CLA treatment. The gene discussed is SELPLG; the disease is myeloid sarcoma.